‹ Back

SaMD, Clinical Decision Support Software, and AI-Enabled Medical Devices: What Innovators Need to Know Before Going to Market

April, 2026 | CAHIR Solutions, Linda McQuade, MD, MBA

 

 

Digital health companies no longer have the luxury of treating regulatory strategy as a late-stage checklist. In the United States, United Kingdom, and major Asian markets, software-based medical technologies are being reviewed through increasingly mature frameworks that focus not just on what a product does, but how it is built, validated, secured, updated, and monitored after launch.

 

For founders, product leaders, clinical teams, and investors, the challenge is not simply understanding whether a product is “regulated.” The real challenge is determining whether a software function is Software as a Medical Device (SaMD), exempt Clinical Decision Support (CDS), regulated CDS, or an AI-enabled medical device subject to additional scrutiny around transparency, performance drift, and lifecycle control.

 

That distinction matters because it shapes the entire commercialization path: product claims, technical documentation, validation strategy, quality management systems, submission route, and post-market obligations. For companies planning to market and sell digital health products across the US, UK, and Asia, an early, harmonized strategy can prevent expensive rework and accelerate market entry.

 

Understanding the Categories

What is SaMD?

Software as a Medical Device is software intended for one or more medical purposes that performs those purposes without being part of a hardware medical device. In practical terms, SaMD is the medical product itself: a diagnostic algorithm, an imaging analysis application, a digital therapeutic, or a cloud-based clinical analysis tool that can run on general-purpose computing platforms.

 

This distinction is foundational because SaMD is regulated as a stand-alone device. Its intended use, risk profile, and claims determine whether it falls into a Class I, II, or III FDA category and whether it proceeds through a 510(k), De Novo, or PMA pathway.

 

What is Clinical Decision Support Software?

Clinical Decision Support software is a broader category that includes tools designed to provide recommendations, alerts, risk scores, or clinical insights to support care decisions. Not all CDS functions are regulated as medical devices in the United States. FDA’s guidance explains that some CDS functions are excluded from the device definition if they meet specific criteria, including enabling a healthcare professional to independently review the basis for the recommendation.

 

That means CDS sits at an important boundary line. Some products remain outside device regulation, while others cross into regulated medical device territory because they influence diagnosis or treatment in ways the user cannot independently assess. For companies developing algorithmic triage, prediction, or recommendation engines, this is often the most critical classification decision in the product lifecycle.

 

What are AI-enabled medical devices?

AI-enabled medical devices are not a separate statutory category under US law. Instead, FDA regulates them through existing medical device pathways, often as SaMD, while applying additional expectations to model development, modification, monitoring, and performance management across the product lifecycle.

In other words, AI usually changes the evidence burden and control strategy more than it changes the legal category. An AI-enabled imaging algorithm may still be SaMD, but it will likely attract deeper scrutiny around training data quality, bias, generalizability, cybersecurity, and model updates over time.

 

The Key Differences — and Similarities

Where they differ

The simplest way to distinguish these categories is to start with intended use and user reliance. SaMD is stand-alone software with a medical purpose. CDS is software that supports decisions, but may or may not be regulated depending on who uses it, how transparent its logic is, and whether the user can independently evaluate the recommendation. AI-enabled device software refers to the use of machine learning or related methods inside a regulated device, frequently within a SaMD product.

A useful rule of thumb is this: if the software directly diagnoses, treats, or drives clinical management, it is more likely to be regulated as a medical device; if it uses AI to do so, its lifecycle controls and evidence requirements become more demanding.

 

Where they overlap

These categories overlap extensively in the real world. A single product can be both SaMD and AI-enabled, and some CDS products are also regulated SaMD if they provide clinically actionable outputs that cannot be independently evaluated by the user.

That is why classification cannot be treated as a labeling exercise. It must be integrated with product claims, UX design, explainability, data strategy, and market-entry planning from the beginning.

 

The Standards That Matter Most

Global frameworks first

The International Medical Device Regulators Forum (IMDRF) remains the most important global reference point for SaMD. FDA and other regulators use the IMDRF framework to support harmonized thinking on software risk, intended use, and lifecycle expectations.

 

For companies targeting multiple regions, this matters because an IMDRF-aligned core dossier is often the most efficient foundation for global expansion. It creates a common language for risk categorization and technical justification even when local submission requirements differ.

 

Software, risk, and cybersecurity controls

Beyond the regulatory frameworks, software medical device programs are expected to stand on mature engineering and quality foundations. In practice, that means software lifecycle discipline, formal risk management, traceability, verification and validation, and secure development practices built into the product lifecycle.

 

For AI-enabled products, these controls extend further into dataset governance, model versioning, change management, and real-world performance monitoring. Regulators increasingly expect manufacturers to show not only that the product works at launch, but that it remains safe and effective as environments, inputs, and clinical usage evolve.

 

 

FDA Compliance Steps Before Marketing in the US

Step 1: Determine whether the software is a device

Step 2: Confirm classification and enter the correct regulatory pathway 

Step 3: Build the quality and documentation infrastructure

Step 4: Generate analytical and clinical evidence

Step 5: Prepare for lifecycle management after clearance

 

UK Market Access: What is Changing

A more reliance-based model is emerging

The UK regulatory landscape is evolving quickly. MHRA’s July 2025 reform package signaled a more reliance-oriented market access approach, including streamlined pathways for certain devices already authorized by FDA, Health Canada, or Australia’s TGA.

 

That shift is especially relevant for SaMD and AI-driven products because it reduces some duplication for companies with a credible prior authorization strategy. It also means that sequencing US and UK submissions can now be a commercial strategy, not just a regulatory one.

 

The UK is also building AI-specific regulatory tools

The MHRA has also invested in the AI Airlock sandbox to explore how novel AI medical devices should be evaluated in a controlled environment. This reflects a broader UK goal: move faster on breakthrough software while keeping targeted scrutiny on higher-risk or more novel AI use cases.

 

For manufacturers, the practical message is clear. The UK is becoming more flexible, but not less demanding. Companies still need robust technical evidence, clear intended use statements, and a market-entry strategy aligned to UK-specific post-market and recognition requirements.

 

Asia: One Region, Many Pathways

Convergence around IMDRF principles

Asia is not a single regulatory market, but many regulators across the region have moved toward IMDRF-aligned approaches for software medical devices. This is good news for digital health companies because it means a well-structured global dossier can often be adapted more efficiently across multiple jurisdictions.

 

Practical differences still matter

Even with broad convergence, local differences remain significant. Submission formatting, language requirements, local representative obligations, and country-specific evidence expectations still affect timelines and cost. In some Asia-Pacific markets, using IMDRF-aligned documentation can reduce overhead, but localization is still essential.

For companies entering Singapore, Japan, China, or other priority markets, the right strategy is usually not “copy and paste” global compliance. It is a core dossier plus local adaptation plan.

 

What Key Stakeholders Care About Most

Regulators want disciplined lifecycle control

Regulators are increasingly focused on whether the manufacturer can explain, validate, secure, and maintain the software over time. This is particularly visible in AI/ML guidance, where lifecycle management and change control now sit alongside premarket evidence as core expectations.

 

Clinicians want trust, transparency, and workflow fit

Clinicians are more likely to adopt software that is explainable, validated in realistic settings, and designed to fit existing workflows. For CDS and AI-enabled tools, the ability of the user to understand and appropriately rely on the output is both a regulatory issue and a market adoption issue.

 

Investors and commercial teams want predictability

Commercial stakeholders care about regulatory clarity because it influences launch timing, product roadmap confidence, and capital efficiency. A product that is misclassified or under-documented can lose months in avoidable remediation, which is why regulatory strategy now plays a central role in product-market fit for digital health.

 

Partner with CAHIR Solutions—and bring your device to market with purpose and precision

At CAHIR Solutions, we help transform innovative devices into market-ready successes—faster, smarter, and with confidence. With 15+ years in regulatory compliance, our practice lead and team bring a clear, evidence-based approach to every stage of your regulatory and commercialization journey, mapping precise pathways that drive measurable results and minimize costs and delays.

From early development through market launch, we provide full-spectrum regulatory and commercial support tailored to your product’s unique needs. Whether you’re navigating complex compliance requirements or preparing for global market access, we ensure every step is aligned, efficient, and strategically sound.
 

What sets us apart is our practice transparency, integrity, open communications, and hands-on partnership. We don’t just advise—we work alongside you as a trusted, reliable extension of your team.